natgillin/translations-raw huggingface dataset:
Some hypertensive patients with no apparent pre-existing renal vascular disease have developed increases in blood urea and serum creatinine, usually minor and transient, especially when< COVERSYL and associated names > has been given concomitantly with a diuretic.
Pri nekaterih bolnikih s hipertenzijo brez očitne že obstoječe ledvične žilne bolezni so se povečale vrednosti sečnine v krvi in kreatinina v serumu, običajno blago in prehodno, zlasti ko so < COVERSYL in sorodna imena > jemali sočasno z diuretikom.
Dosage reduction and/ or discontinuation of the diuretic and/ or< COVERSYL and associated names > may be required.
Včasih je treba zmanjšati odmerek ali ukiniti diuretik ali < COVERSYL in sorodna imena > ali oba.
There is no experience regarding the administration of< COVERSYL and associated names > in patients with a recent kidney transplantation.
Pri bolnikih z nedavno presaditvijo ledvic ni izkušenj z uporabo zdravila < COVERSYL in sorodna imena >.
Hypersensitivity/ Angioedema:
Preobčutljivost in angioedem:
Angioedema of the face, extremities, lips, mucous membranes, tongue, glottis and/ or larynx has been reported rarely in patients treated with ACE inhibitors, including< COVERSYL and associated names > (see 4.8 Undesirable effects).
Pri bolnikih, ki so jemali zaviralce angiotenzinske konvertaze, vključno z zdravilom < COVERSYL in sorodna imena >, so redko poročali o angioedemu obraza, okončin, ustnic, sluznic, jezika ter glotisa ali grla ali obeh (glejte poglavje 4. 8 Neželeni učinki).
In such cases ,< COVERSYL and associated names > should promptly be discontinued and appropriate monitoring should be initiated and continued until complete resolution of symptoms has occurred.
V teh primerih morate zdravilo < COVERSYL in sorodna imena > takoj ukiniti in bolnika ustrezno spremljati, kar nadaljujete do popolnega izginotja simptomov.
This may include the administration of adrenaline and/ or the maintenance of a patent airway.
Kadar zajame jezik, glotis ali grlo in grozi zapora dihalnih poti, je potrebno takojšnje urgentno zdravljenje, ki obsega dajanje adrenalina, ohranjanje odprtih dihalnih poti ali oboje.
Patients with a history of angioedema unrelated to ACE inhibitor therapy may be at increased risk of angioedema while receiving an ACE inhibitor (see 4.3 Contraindications).
14 EMEA 2005 Bolnike z angiodemom v anamnezi, ki ni bil povezan z zdravljenjem z zaviralci angiotenzinske konvertaze, lahko spremlja povečano tveganje za angioedem ob jemanju zaviralca angiotenzinske konvertaze (glejte poglavje 4. 3 Kontraindikacije).
Anaphylactoid reactions during low-density lipoproteins (LDL) apheresis:
Anafilaktoidne reakcije med aferezo lipoproteinov majhne gostote (LDL):
Rarely, patients receiving ACE inhibitors during low-density lipoprotein (LDL) apheresis with dextran sulphate have experienced life-threatening anaphylactoid reactions.
Bolniki, ki so jemali zaviralce angiotenzinske konvertaze med aferezo lipoproteinov majhne gostote z dekstranovim sulfatom, so v redkih primerih doživeli smrtno nevarne anafilaktoidne reakcije.
Patients receiving ACE inhibitors during desensitisation treatment (e. g. hymenoptera venom) have experienced anaphylactoid reactions.
Bolniki, ki so jemali zaviralce angiotenzinske konvertaze med desenzibilizacijskim zdravljenjem (na primer s strupom kožokrilcev), so imeli anafilaktoidne reakcije.
Hepatic failure:
Bolniki z jetrnim popuščanjem:
Patients receiving ACE inhibitors who develop jaundice or marked elevations of hepatic enzymes should discontinue the ACE inhibitor and receive appropriate medical follow-up (see 4.8 Undesirable effects).
Če se pri bolnikih, ki jemljejo zaviralce angiotenzinske konvertaze, pojavi zlatenica ali izrazito povečanje vrednosti jetrnih encimov, jim morate ukiniti zaviralec angiotenzinske konvertaze in jih ustrezno zdravniško spremljati (glejte poglavje 4. 8 Neželeni učinki).
13  EMEA 2005 Neutropenia/ Agranulocytosis/ Thrombocytopenia/ Anaemia:
Nevtropenija, agranulocitoza, trombocitopenija, anemija:
Neutropenia/ agranulocytosis, thrombocytopenia and anaemia have been reported in patients receiving ACE inhibitors.
Pri bolnikih, ki so jemali zaviralce angiotenzinske konvertaze, so poročali o nevtropeniji, agranulocitozi, trombocitopeniji in anemiji.
Race:
Etnična pripadnost:
ACE inhibitors cause a higher rate of angioedema in black patients than in non-black patients.
Zaviralci angiotenzinske konvertaze pogosteje povzročajo angioedem pri črncih kot pri bolnikih iz drugih etničnih skupin.
Cough has been reported with the use of ACE inhibitors.
Ob jemanju zaviralcev angiotenzinske konvertaze so poročali o kašlju.
Characteristically, the cough is non- productive, persistent and resolves after discontinuation of therapy.
Zanj je značilno, da je neproduktiven, trdovraten in izgine po prekinitvi zdravljenja.
ACE inhibitor-induced cough should be considered as part of the differential diagnosis of cough.
Pri njegovi diferencialni diagnozi upoštevajte tudi kašelj zaradi zaviralcev angiotenzinske konvertaze.
Surgery/ Anaesthesia:
15 EMEA 2005 Kirurški posegi in anestezija:
In patients undergoing major surgery or during anaesthesia with agents that produce hypotension ,< COVERSYL and associated names > may block angiotensin II formation secondary to compensatory renin release.
Pri bolnikih, ki prestajajo večji kirurški poseg ali so prejeli anestezijo s hipotenzivnimi zdravili, lahko < COVERSYL in sorodna imena > zavira tvorjenje angiotenzina II, sekundarno po kompenzacijskem sproščanja renina.
Elevations in serum potassium have been observed in some patients treated with ACE inhibitors, including perindopril.
Pri nekaterih bolnikih, ki so jemali zaviralce angiotenzinske konvertaze, vključno s perindoprilom, so opažali povečanje vrednosti kalija v serumu.
Patients at risk for the development of hyperkalaemia include those with renal insufficiency, uncontrolled diabetes mellitus, or those using concomitant potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes; or those patients taking other drugs associated with increases in serum potassium (e. g. heparin).
Tveganje za nastanek hiperkalemije spremlja na primer bolnike z ledvičnim popuščanjem, neurejeno sladkorno boleznijo ali tiste, ki sočasno jemljejo diuretike, ki zadržujejo kalij, dodatke kalija ali nadomestke soli, ki vsebujejo kalij, pa tudi bolnike, ki jemljejo druga zdravila, povezana s povečanjem vrednosti kalija v serumu (na primer heparin).
If concomitant use of the above- mentioned agents is deemed appropriate, regular monitoring of serum potassium is recommended.
Če menite, da je sočasno jemanje naštetih zdravil ustrezno, je priporočljivo redno merjenje ravni kalija v serumu.
(See 4.5 Interaction with other medicinal products and other forms of interaction, Antidiabetics.)
Pri bolnikih s sladkorno boleznijo, ki jemljejo peroralne antidiabetike ali insulin, morate pazljivo spremljati urejenost glukoze v krvi v prvem mesecu zdravljenja z zaviralci angiotenzinske konvertaze (glejte poglavje 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij, Antidiabetiki).
The combination of lithium and perindopril is generally not recommended (see 4.5 Interaction with other medicinal products and other forms of interaction).
Kombinacija litija in perindoprila na splošno ni priporočljiva (glejte poglavje 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij).
Potassium sparing diuretics, potassium supplements or potassium-containing salt substitutes:
Diuretiki, ki zadržujejo kalij, dodatki kalija ali nadomestki soli, ki vsebujejo kalij:
The combination of perindopril and potassium sparing diuretics, potassium supplements or potassium- containing salt substitutes is generally not recommended (see 4.5 Interaction with other medicinal products and other forms of interaction).
Kombinacija perindoprila in diuretikov, ki zadržujejo kalij, dodatkov kalija ali nadomestkov soli, ki vsebujejo kalij, na splošno ni priporočljiva (glejte poglavje 4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij).
(See section 4.3 “ Contraindications” and section 4.6 “ Pregnancy and lactation”).
(Glejte poglavji 4. 3 Kontraindikacije ter 4. 6 Nosečnost in dojenje.)
14  EMEA 2005 4.5 Interaction with other medicinal products and other forms of interaction
4. 5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij
Diuretics:
Diuretiki:
Patients on diuretics, and especially those who are volume and/ or salt depleted, may experience excessive reduction in blood pressure after initiation of therapy with an ACE inhibitor.
Bolnikom, ki jemljejo diuretike, ali imajo hipovolemijo, pomanjkanje soli ali oboje, se lahko preveč zniža krvni tlak po uvedbi zaviralca angiotenzinske konvertaze.
Potassium sparing diuretics (e. g. spironolactone, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.
Diuretiki, ki zadržujejo kalij (na primer spironolakton, triamteren ali amilorid), kalijevi dodatki ali nadomestki soli, ki vsebujejo kalij, lahko signifikantno povečajo vrednost kalija v serumu.
Therefore the combination of perindopril with the above-mentioned drugs is not recommended (see section 4.4).
Kombinacija perindoprila z naštetimi zdravili torej ni priporočljiva (glejte poglavje 4. 4).
Use of perindopril with lithium is not recommended, but if the combination proves necessary, careful monitoring of serum lithium levels should be performed (see section 4.4).
Jemanje perindoprila ob litiju ni priporočljivo, če je ta kombinacija vendarle potrebna, morate pozorno spremljati vrednost litija v serumu (glejte poglavje 4. 4).
Non-steroidal anti-inflammatory drugs (NSAIDs) including aspirin ≥ 3 g/ day:
16 EMEA 2005 Nesteroidni antirevmatiki, vključno z Aspirinom ≥ 3 g na dan:
Perindopril may be used concomitantly with acetylsalicylic acid (when used as a thrombolytic), thrombolytics, beta-blockers and/ or nitrates.
Perindopril lahko uporabljate sočasno z acetilsalicilno kislino (kot trombolitikom), trombolitiki, blokatorji beta receptorjev, nitrati ali vsemi.
Tricyclic antidepressants/ Antipsychotics/ Anesthetics:
Triciklični antidepresivi, antipsihotiki, anestetiki:
Concomitant use of certain anaesthetic medicinal products, tricyclic antidepressants and antipsychotics with ACE inhibitors may result in further reduction of blood pressure (see section 4.4).
Sočasna uporaba določenih anestetikov, tricikličnih antidepresivov in antipsihotikov z zaviralci angiotenzinske konvertaze lahko povzroči nadaljnje zniževanje krvnega tlaka (glejte poglavje 4. 4).
Sympathomimetics:
Simpatikomimetiki:
Sympathomimetics may reduce the antihypertensive effects of ACE inhibitors.
Simpatikomimetiki lahko zmanjšajo antihipertenzivni učinek zaviralcev angiotenzinske konvertaze.
Pregnancy :< COVERSYL and associated names > should not be used during the first trimester of pregnancy.
4. 6 Nosečnost in dojenje
Controlled studies with ACE inhibitors have not been done in humans, but in a 15  EMEA 2005 limited number of cases with first trimester exposure there do not appear to have been any malformations consistent with human foetotoxicity as described below.
Pri ljudeh niso izvajali nadzorovanih študij z zaviralci angiotenzinske konvertaze, toda pri omejenem številu bolnic, ki so bile zdravilu izpostavljene v prvem trimesečju nosečnosti, niso opazili nikakršnih malformacij v smislu fetotoksičnosti pri ljudeh, ki je opisana v nadaljevanju.
Prolonged ACE inhibitor exposure during the second and third trimesters is known to induce human foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia).
Znano je, da podaljšana izpostavljenost zaviralcem angiotenzinske konvertaze v drugem in tretjem trimesečju pri ljudeh povzroča fetotoksičnost (zmanjšano delovanje ledvic, oligohidramnij, upočasnjeno osifikacijo lobanje) in toksičnost pri novorojenčkih (ledvično popuščanje, hipotenzijo, hiperkalemijo) (glejte poglavje 5. 3 Predklinični podatki o varnosti).
(See 5.3 “ Preclinical safety data”) Should exposure to perindopril have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.
Če je bolnica v drugem trimesečju nosečnosti ali pozneje izpostavljena perindoprilu, je priporočljiv ultrazvočni pregled ledvičnega delovanja in lobanje.
Therefore the use of< COVERSYL and associated names > is not recommended in women who are breast-feeding.
Zato predpisovanje zdravila < COVERSYL in sorodna imena > doječim materam ni priporočljivo.
4.7 Effects on ability to drive and use machines
17 EMEA 2005 4. 7 Vpliv na sposobnost vožnje in upravljanja s stroji
Very common (> 1/ 10); common (> 1/ 100 ,< 1/10); uncommon (> 1/1000 ,< 1/100); rare (> 1/ 10000 ,< 1/1000); very rare (< 1/10000), including isolated reports.
zelo pogosti (> 1/ 10), pogosti (> 1/ 100, < 1/ 10), občasni (> 1/ 1. 000, < 1/ 100), redki (> 1/ 10. 000, < 1/ 1. 000), zelo redki (< 1/ 10. 000), vključno s posameznimi primeri.
Uncommon: mood or sleep disturbances
Občasni: motnje razpoloženja ali spanja.
Common: headache, dizziness, vertigo, paresthaesia Very rare: confusion
Zelo redki: zmedenost.
Common: vision disturbance
Pogosti: motnje vida.
Common: tinnitus
Pogosti: tinitus.
Cardio-vascular disorders:
Srčnožilne bolezni:
Common: hypotension and effects related to hypotension Very rare: arrhythmia, angina pectoris, myocardial infarction and stroke, possibly secondary to excessive hypotension in high-risk patients (see 4.4 Special warnings and special precautions for use).
Zelo redki: aritmije, angina pektoris, miokardni infarkt in možganska kap, verjetno sekundarno kot posledica prevelike hipotenzije pri bolnikih z velikim tveganjem (glejte 4. 4 Posebna opozorila in previdnostni ukrepi).
Common: cough, dyspnoea Uncommon: bronchospasm Very rare: eosinophilic pneumonia, rhinitis
Zelo redki: eozinofilna pljučnica, rinitis.
Common: nausea, vomiting, abdominal pain, dysgeusia, dyspepsia, diarrhoea, constipation Uncommon: dry mouth Very rare: pancreatitis
Zelo redki: pankreatitis.
Very rare: hepatitis either cytolytic or cholestatic (see section 4.4 Special warnings and special precautions for use)
Zelo redki: hepatitis, bodisi citolitični ali holestatični (glejte 4. 4 Posebna opozorila in previdnostni ukrepi).
16  EMEA 2005 Skin and subcutaneous tissue disorders:
Pogosti: izpuščaji, srbenje.
Common: rash, pruritus Uncommon: angioedema of face, extremities, lips, mucous membranes, tongue, glottis and/ or larynx, urticaria (see 4.4 Special warnings and special precautions for use).
Občasni: angioedem obraza, okončin, ustnic, sluznic, jezika ter glotisa ali grla ali obeh, koprivnica (glejte 4. 4 Posebna opozorila in previdnostni ukrepi).
Common: muscle cramps
Pogosti: mišični krči.
Uncommon: renal insufficiency Very rare: acute renal failure
18 EMEA 2005 Zelo redki: akutno ledvično popuščanje.
Uncommon: impotence
Občasni: impotenca.
Common: asthenia Uncommon: sweating
Občasni: potenje.
Decreases in haemoglobin and haematocrit, thrombocytopenia, leucopenia/ neutropenia, and cases of agranulocytosis or pancytopenia, have been reported very rarely.
Zelo redko so opažali zmanjšanje hemoglobina in hematokrita, trombocitopenijo, levkopenijo in nevtropenijo ter primere agranulocitoze ali pancitopenije.
In patients with a congenital deficiency of G-6PDH, very rare cases of haemolytic anaemia have been reported (see section 4.4 Special warnings and special precautions for use).
Pri bolnikih s prirojenim pomanjkanjem glukoza- 6- fosfatne dehidrogenaze so zelo redko poročali o hemolitični anemiji (glejte poglavje 4. 4 Posebna opozorila in previdnostni ukrepi).
Few patients experienced serious adverse events:
Doživelo jih je malo bolnikov:
16 (0.3%) of the 6122 perindopril patients and 12 (0.2%) of the 6107 placebo patients.
16 (0, 3%) od 6122 bolnikov, ki so jemali perindopril in 12 (0, 2%) od 6107 bolnikov, ki so jemali placebo.
In perindopril-treated patients, hypotension was observed in 6 patients, angioedema in 3 patients and sudden cardiac arrest in 1 patient.
Ob perindoprilu so opazili hipotenzijo pri 6 bolnikih, angioedem pri 3 in nenaden zastoj srca pri 1.
More patients withdrew for cough, hypotension or other intolerance on perindopril than on placebo, 6.0% (n=366) versus 2.1% (n=129) respectively.
6, 0% (n = 366) proti 2, 1% (n = 129).
If available, treatment with angiotensin II infusion and/ or intravenous catecholamines may also be considered.
Premislite tudi o zdravljenju z infuzijo angiotenzina II, intravenskimi kateholamini ali obojim, če je na voljo.
Perindopril may be removed from the general circulation by haemodialysis.
Perindopril lahko odstranite iz splošnega krvnega obtoka s hemodializo (glejte poglavje 4. 4 Posebna opozorila in previdnostni ukrepi, Bolniki na hemodializi).
(See 4.4 Special warnings and special precautions for use, Haemodialysis Patients.) Pacemaker therapy is indicated for therapy-resistant bradycardia.
Srčni spodbujevalnik je indiciran pri bolnikih z bradikardijo, ki se ne odziva na zdravljenje.
C09A A04 Perindopril is an inhibitor of the enzyme that converts angiotensin I into angiotensin II (Angiotensin Converting Enzyme ACE).
Perindopril je zaviralec angiotenzinske konvertaze (ACE), encima, ki pretvarja angiotenzin I v angiotenzin II.
Since ACE inactivates bradykinin, inhibition of ACE also results in an increased activity of circulating and local kallikrein- kinin systems (and thus also activation of the prostaglandin system).
Ker angiotenzinska konvertaza inaktivira bradikinin, njeno zaviranje privede tudi do povečane aktivnosti kalikreinsko - 19 EMEA 2005 kininskega sistema v krvnem obtoku in lokalno (in s tem tudi do aktivacije prostaglandinskega sistema).
It is possible that this mechanism contributes to the blood pressure-lowering action of ACE inhibitors and is partially responsible for certain of their side effects (e. g. cough).
Možno je, da ta mehanizem prispeva k antihipertenzivnemu učinku zaviralcev angiotenzinske konvertaze in da je delno odgovoren za nekatere njihove neželene učinke, na primer kašelj.
Perindopril is active in all grades of hypertension: mild, moderate, severe; a reduction in systolic and diastolic blood pressures in both supine and standing positions is observed.
Znižata se tako sistolični kot diastolični krvni tlak, leže in stoje.
The antihypertensive activity is maximal between 4 and 6 hours after a single dose and is sustained for at least 24 hours: trough effects are about 87-100% of peak effects.
Antihipertenzivni učinek je največji 4 do 6 ur po enkratnem odmerku in traja najmanj 24 ur: najmanjši učinek znaša približno 87 do 100% največjega učinka.
Heart failure :< COVERSYL and associated names > reduces cardiac work by a decrease in pre-load and after-load.
Srčno popuščanje: < COVERSYL in sorodna imena > zmanjšuje delo srca tako, da zmanjšuje predobremenitev in poobremenitev.
Studies in patients with heart failure have demonstrated:
Študije pri bolnikih s srčnim popuščanjem so pokazale:
- decreased left and right ventricular filling pressures,
- zmanjšanje polnilnega tlaka levega in desnega prekata,
- reduced total peripheral vascular resistance,
- zmanjšanje skupnega perifernega žilnega upora,
- increased cardiac output and improved cardiac index.
- povečanje minutnega volumna srca in izboljšanje srčnega indeksa.
In comparative studies, the first administration of 2 mg of< COVERSYL and associated names > to patients with mild to moderate heart failure was not associated with any significant reduction of blood pressure as compared to placebo.
V primerjalnih študijah prvi 2- mg odmerek zdravila < COVERSYL in sorodna imena > pri bolnikih z blagim do zmernim srčnim popuščanjem ni signifikantno znižal krvnega tlaka v primerjavi s placebom.
The EUROPA study was a multicentre, international, randomised, double-blind, placebo-controlled clinical trial lasting 4 years.
Študija EUROPA je bila multicentrično, mednarodno, randomizirano, dvojno slepo, s placebom nadzorovano klinično preskušanje, ki je trajalo 4 leta.
Twelve thousand two hundred and eighteen (12218) patients aged over 18 were randomised to perindopril 8 mg (n=6110) or placebo (n=6108).
Naključno so razvrstili dvanajst tisoč dvesto osemnajst (12218) bolnikov, starejših od 18 let, ki so prejemali perindopril v odmerku po 8 mg (n=6110) ali placebo (n=6108).
The trial population had evidence of coronary artery disease with no evidence of clinical signs of heart failure.
Proučevani bolniki so imeli koronarno arterijsko bolezen brez opaženih kliničnih znakov srčnega popuščanja.
Overall, 90% of the patients had a previous myocardial infarction and/ or a previous coronary revascularisation.
Skupno je 90% bolnikov imelo miokardni infarkt ali revaskularizacijo koronarnih arterij ali oboje v anamnezi.
Most of the patients received the study medication on top of conventional therapy including platelet inhibitors, lipid lowering agents and beta-blockers.
20 EMEA 2005 zdravljenja, ki je vključevalo zaviralce agregacije trombocitov, zdravila za zniževanje lipidov in blokatorje beta receptorjev.
18  EMEA 2005 The main efficacy criterion was the composite of cardiovascular mortality, non fatal myocardial infarction and/ or cardiac arrest with successful resuscitation.
Poglavitno merilo učinkovitosti je bil sestavljeni rezultat s srčnožilno umrljivostjo in miokardnim infarktom brez smrtnega izida ali srčnim zastojem z uspešnim oživljanjem ali obema.
The treatment with perindopril 8 mg once daily resulted in a significant absolute reduction in the primary endpoint of 1.9% (relative risk reduction of 20%, 95%CI [9.4; 28.6] – p < 0.001).
Zdravljenje s perindoprilom v odmerku 8 mg enkrat na dan je signifikantno absolutno zmanjšalo poglavitni sestavljeni rezultat za 1, 9% (zmanjšanje sorazmernega tveganja za 20%, 95 -% interval zaupanja [9, 4 do 28, 6]; p < 0, 001).
In patients with a history of myocardial infarction and/ or revascularisation, an absolute reduction of 2.2% corresponding to a RRR of 22.4% (95%CI [12.0; 31.6] – p < 0.001) in the primary endpoint was observed by comparison to placebo.
Pri bolnikih z miokardnim infarktom ali revaskularizacijo ali obema v anamnezi so opazili absolutno zmanjšanje za 2, 2%, ki ustreza 22, 4 -% zmanjšanju relativnega tveganja za poglavitni izid (95 -% interval zaupanja [12, 0 do 31, 6]; p < 0, 001) v primerjavi s placebom.
Bioavailability is 65 to 70%.
Biološka uporabnost znaša od 65 do 70%.
About 20% of the total quantity of perindopril absorbed is converted into perindoprilat, the active metabolite.
Približno 20% skupne absorbirane količine perindoprila se pretvori v aktivni presnovek perindoprilat.
As ingestion of food decreases conversion to perindoprilat, hence bioavailability ,< COVERSYL and associated names > should be administered orally in a single daily dose in the morning before a meal.
Ker uživanje hrane zmanjšuje pretvorbo v perindoprilat in zato tudi biološko uporabnost, morajo bolniki zdravilo < COVERSYL in sorodna imena > jemati peroralno v enem odmerku na dan, zjutraj pred obrokom.
The volume of distribution is approximately 0.2 l/ kg for unbound perindoprilat.
Volumen porazdelitve je pri nevezanem perindoprilatu približno 0, 2 l/ kg.
Protein binding is slight (binding of perindoprilat to angiotensin converting enzyme is less than 30%), but is concentration-dependent.
Vezava na beljakovine je majhna (vezava perindoprilata na angiotenzinsko konvertazo je manjša od 30%), a odvisna od koncentracije.
Dissociation of perindoprilat bound to angiotensin converting enzyme leads to an “ effective” elimination half-life of 25 hours, resulting in steady-state within 4 days.
Disociacija perindoprilata, vezanega na angiotenzinsko konvertazo, vodi do 'efektivne' razpolovne dobe izločanja 25 ur, ravnovesno stanje pa je doseženo v 4 dneh.
Dialysis clearance of perindoprilat is equal to 70 ml/ min.
Dializni očistek perindoprilata je 70 ml/ min.
Perindopril kinetics are modified in patients with cirrhosis: hepatic clearance of the parent molecule is reduced by half.
Kinetika perindoprila je spremenjena pri bolnikih s cirozo: pri njih se jetrni očistek osnovne molekule zmanjša za polovico.